SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ -- Willow Biosciences Inc., ("Willow") (TSX:WLLW.TO) (OTCQB:CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation. Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process.
Read more at prnewswire.comWILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
PR Newswire -
Tue Oct 3, 2023
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
